Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced its upcoming conference call scheduled for May 5, 2022, at 5:00 PM ET to discuss financial results for Q1 2022. The call will provide updates on the company's performance and strategy in treating rare genetic diseases. Investors can participate via phone or access a live and recorded webcast on the company’s website. Ultragenyx is focused on developing novel therapies for serious rare and ultra-rare genetic disorders, emphasizing time-efficient drug development to meet patient needs.
- None.
- None.
NOVATO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 5:00pm ET to discuss its financial results and corporate update for the quarter ended March 31, 2022.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call by phone, dial
(855) 797-6910 (USA) or (262) 912-6260 (International) and enter the passcode 7951356. The replay of the call will be available for one year.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts
Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
415-660-0951
Media
Jeff Blake
415-612-7784
media@ultragenyx.com
FAQ
When is the Ultragenyx Pharmaceutical Inc. conference call?
What will Ultragenyx Pharmaceutical discuss during the conference call?
How can I listen to the Ultragenyx conference call?
What is the focus of Ultragenyx Pharmaceutical?
